Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma

被引:13
|
作者
Baltanas, Fernando C. [1 ,2 ,3 ,4 ]
Garcia-Navas, Rosula [1 ,2 ]
Rodriguez-Ramos, Pablo [1 ,2 ]
Calzada, Nuria [1 ,2 ]
Cuesta, Cristina [5 ]
Borrajo, Javier [6 ]
Fuentes-Mateos, Rocio [1 ,2 ]
Olarte-San Juan, Andrea [1 ,2 ]
Vidana, Nerea [1 ,2 ]
Castellano, Esther [5 ]
Santos, Eugenio [1 ,2 ]
机构
[1] Univ Salamanca, Inst Canc Mol & Cellular Biol, Canc Res Ctr, Lab 1,CSIC, Salamanca 37007, Spain
[2] CIBERONC, Salamanca 37007, Spain
[3] Univ Seville, CSIC, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBiS, Seville, Spain
[4] Univ Seville, Dept Med Physiol & Biophys, Seville, Spain
[5] Univ Salamanca, Inst Canc Mol & Cellular Biol, Canc Res Ctr, Lab 5,CSIC, Salamanca 37007, Spain
[6] Univ Salamanca, Dept Biomed Sci & Diagnost, Salamanca 37007, Spain
关键词
K-RAS; CANCER; PROMOTES; KRAS; ACTIVATION;
D O I
10.1038/s41467-023-41583-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The impact of genetic ablation of SOS1 or SOS2 is evaluated in a murine model of KRAS(G12D)-driven lung adenocarcinoma (LUAD). SOS2 ablation shows some protection during early stages but only SOS1 ablation causes significant, specific long term increase of survival/lifespan of the KRAS(G12D) mice associated to markedly reduced tumor burden and reduced populations of cancer-associated fibroblasts, macrophages and T-lymphocytes in the lung tumor microenvironment (TME). SOS1 ablation also causes specific shrinkage and regression of LUAD tumoral masses and components of the TME in pre-established KRAS(G12D) LUAD tumors. The critical requirement of SOS1 for KRAS(G12D)-driven LUAD is further confirmed by means of intravenous tail injection of KRAS(G12D) tumor cells into SOS1KO/KRASWT mice, or of SOS1-less, KRAS(G12D) tumor cells into wildtype mice. In silico analyses of human lung cancer databases support also the dominant role of SOS1 regarding tumor development and survival in LUAD patients. Our data indicate that SOS1 is critically required for development of KRAS(G12D)-driven LUAD and confirm the validity of this RAS-GEF activator as an actionable therapeutic target in KRAS mutant LUAD.
引用
收藏
页数:16
相关论文
共 47 条
  • [21] A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis
    Whipple, C. A.
    Young, A. L.
    Korc, M.
    ONCOGENE, 2012, 31 (20) : 2535 - 2544
  • [22] Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer model
    Baumgart, A.
    Mazur, P. K.
    Anton, M.
    Rudelius, M.
    Schwamborn, K.
    Feuchtinger, A.
    Behnke, K.
    Walch, A.
    Braren, R.
    Peschel, C.
    Duyster, J.
    Siveke, J. T.
    Dechow, T.
    ONCOGENE, 2015, 34 (05) : 578 - 588
  • [23] Targeting NUPR1-dependent stress granules formation to induce synthetic lethality in KrasG12D-driven tumors
    Santofimia-Castano, Patricia
    Fraunhoffer, Nicolas
    Liu, Xi
    Bessone, Ivan Fernandez
    di Magliano, Marina Pasca
    Audebert, Stephane
    Camoin, Luc
    Estaras, Matias
    Breniere, Manon
    Modesti, Mauro
    Lomberk, Gwen
    Urrutia, Raul
    Soubeyran, Philippe
    Neira, Jose Luis
    Iovanna, Juan
    EMBO MOLECULAR MEDICINE, 2024, 16 (03) : 475 - 505
  • [24] Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA
    Rakhit, Callum P.
    Trigg, Ricky M.
    Le Quesne, John
    Kelly, Michael
    Shaw, Jacqueline A.
    Pritchard, Catrin
    Martins, L. Miguel
    DISEASE MODELS & MECHANISMS, 2019, 12 (02)
  • [25] PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
    Ni, Qian-Zhi
    Zhu, Bing
    Ji, Yan
    Zheng, Qian-Wen
    Liang, Xin
    Ma, Ning
    Jiang, Hao
    Zhang, Feng-Kun
    Shang, Yu-Rong
    Wang, Yi-Kang
    Xu, Sheng
    Zhang, Er-Bin
    Yuan, Yan-Mei
    Chen, Tian-Wei
    Yin, Fen-Fen
    Cao, Hui-Jun
    Huang, Jing-Yi
    Xia, Ji
    Ding, Xu-Fen
    Qiu, Xiao-Song
    Ding, Kai
    Song, Chao
    Zhou, Wen-Tao
    Wu, Meng
    Wang, Kang
    Lui, Rui
    Lin, Qiu
    Chen, Wei
    Li, Zhi-Gang
    Cheng, Shu-Qun
    Wang, Xiao-Fan
    Xie, Dong
    Li, Jing-Jing
    ADVANCED SCIENCE, 2023, 10 (02)
  • [26] KrasG12D and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung
    Maeda, Yutaka
    Tsuchiya, Tomoshi
    Hao, Haiping
    Tompkins, David H.
    Xu, Yan
    Mucenski, Michael L.
    Du, Lingling
    Keiser, Angela R.
    Fukazawa, Takuya
    Naomoto, Yoshio
    Nagayasu, Takeshi
    Whitsett, Jeffrey A.
    JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (12): : 4388 - 4400
  • [27] The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
    McDaid, W. J.
    Wilson, L.
    Adderley, H.
    Martinez-Lopez, A.
    Baker, M. J.
    Searle, J.
    Ginn, L.
    Budden, T.
    Aldea, M.
    Marinello, A.
    Aredo, J. V.
    Viros, A.
    Besse, B.
    Wakelee, H. A.
    Blackhall, F.
    Castillo-Lluva, S.
    Lindsay, C. R.
    Malliri, A.
    MOLECULAR CANCER, 2024, 23 (01)
  • [28] STAT1 suppresses KRAS-driven lung adenocarcinoma depending on the tumor microenvironment
    Trenk, Christoph
    Sagmeister, Rebecca
    Horvath, Jaqueline
    Homolya, Monika
    Luca, Andreea Corina
    Eferl, Robert
    Moll, Herwig
    Casanova, Emilio
    CANCER RESEARCH, 2023, 83 (07)
  • [29] The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
    McDaid, William J.
    Wilson, Leah
    Adderley, Helen
    Baker, Martin
    Searle, Joshua
    Budden, Timothy
    Viros, Amaya
    Aldea, Mihaela
    Marinello, Arianna
    Aredo, Jacqueline
    Besse, Benjamin
    Wakelee, Heather A.
    Lindsay, Colin R.
    Malliri, Angeliki
    CANCER RESEARCH, 2024, 84 (06)
  • [30] SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD
    Baltanas, Fernando C.
    Kramer-Drauberg, Maximilian
    Garcia-Navas, Rosula
    Patrucco, Enrico
    Petrini, Ettore
    Arnhof, Heribert
    Olarte-SanJuan, Andrea
    Rodriguez-Ramos, Pablo
    Borrajo, Javier
    Calzada, Nuria
    Castellano, Esther
    Mair, Barbara
    Kostyrko, Kaja
    Hofmann, Marco H.
    Ambrogio, Chiara
    Santos, Eugenio
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2025, 122 (11)